A Phase 2 Study of the Halichondrin B Analog E7389 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a Taxane.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jul 2009 Planned end date changed from 1 Feb 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.